StockData

Septerna vs Viking Therapeutics

SEPN and VKTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SEPN and VKTX compare

Viking Therapeutics is the larger company, worth 1.8 times as much as Septerna ($3.4B against $1.9B).

Septerna scores higher on the StockData Score (8 against 5 for Viking Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSEPNVKTX
Size and price
Market cap$1.9B$3.4B
Share price$40.02$26.88
Change, 1 year72.0%−31.3%
Change, 5 years–400%
Beta (5Y)0.701.24
Employees13053
StockData Score
Total score8 (better)5
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S19.4×–
P/B4.4× (better)5.8×
FCF yield−4.2%–
Fair value$15.08–
Margin of safety−165%–
Growth
Revenue growth (TTM)337%–
Profitability
Operating margin−76.2%–
Net margin−61.3%–
FCF margin−80.6%–
Return on equity−14.4% (better)−96.4%
Financial health
Debt / equity0.000.00
Current ratio4.847.27 (better)
Altman Z-score5.91 (better)2.25
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%59.4%
Held by insiders27.9%2.7%
Insider net buying, 12 months−$80.9M−$18.2M (better)
Short interest, % of float10.0%19.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.